Page URL:

NHS may be infringing on DNA patents

22 August 2011
Appeared in BioNews 621


The NHS may be at risk of being sued over patent infringement, says a new report published by the Human Genetics Commission (HGC), the UK Government's genetics advisory body.

At a meeting held to launch the report on DNA patents, experts warned that public sector health workers who regularly use diagnostic genetic tests protected by patents developed in the private sector may be ignoring intellectual property (IP) rights.

The report highlights a 'profound tension between the industry's desire to exploit the financial value of biomarker patents and the routine infringement of such IP in NHS laboratories'. It urges policymakers to begin to address the issue.

The granting of these patents is seen as controversial and unjustifiable by some within the NHS. Gail Norbury, commissioning and governance director of the Genetics Labs at Guy's Hospital, London, said: 'The view from the NHS is that, for diagnostics, gene patents are unacceptable, unenforceable and detrimental to the delivery of patient services'.

Alastair Kent, the chairman of the HGC's IP monitoring group and director of Genetic Alliance UK, said that it was unlikely that companies would sue hospital laboratories that occasionally use a test that infringed a patent. 'I think there would be a very strong patient and public kick back against any company that was seen to be demanding excessive royalties for providing the opportunity for patients with severe and life threatening diseases getting a diagnosis', he said.

Unlike the USA, where more patents are filed and enforced, the UK has so far avoided seeing large-scale litigation in this area. But companies that have invested heavily in the development of patented techniques may soon be looking for a return.

'The fact that they have not been enforced in the UK so far is that generally the amounts of money have been small and many companies shy away from suing hospitals', said Dr Michael Hopkins of the Science Policy Research Unit, University of Sussex. 'But as the sums of money increase it's more likely companies will assert their intellectual property rights'.

Indeed some believe the UK's approach to patent enforcement may push biotechnology companies towards jurisdictions where patents are more readily enforced. Chief scientist of Cambridge-based Lab21 Dr Berwyn Clarke said: 'The UK should be one of the best countries in the world to operate but at the moment it is one of the worst'.

The HGC made several recommendations including a review of licensing guidelines and government monitoring of the use of IP-sensitive genetic tests and their impact on healthcare diagnosis.

Doctors in danger of infringing test patents
Independent |  6 August 2011
HGC Seminar Report on Intellectual Property and DNA Diagnostics
Human Genetics Commission |  5 August 2011
NHS hospitals face DNA patent law suits
Daily Telegraph |  5 August 2011
NHS ignores gene patents, experts say
Financial Times |  5 August 2011
NHS laboratories are infringing DNA patents with cheap “home brew” tests, says Human Genetics Commission
BMJ |  8 August 2011
U.K. Needs to Stop 'Muddling' on Gene Patents, Says Report
Science Insider |  5 August 2011
23 January 2012 - by Ayesha Ahmad 
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C....
19 December 2011 - by Nishat Hyder 
A patent for a diagnostic test is currently under consideration by the US Supreme Court. The eventual decision may have profound implications for the burgeoning 'personalised medicine' industry which often relies on DNA tests to guide physicians in choosing tailored therapies for patients...
14 November 2011 - by Martin Turner 
In what appears to be the end of a long running legal saga, a ruling by the UK's Supreme Court has found in favour of a patent for a gene and the protein sequence it encodes. Lawyers say that the ruling will make it easier to patent discoveries which do not have a clear demonstrated application, a result that will largely please the private bioscience industry but may alarm many who believe that human genes should not be patentable....
12 September 2011 - by Julianna Photopoulos 
A new report published by the Royal College of Physicians, Royal College of Pathologists and British Society for Human Genetics has encouraged the sharing of genetic information between family members and healthcare professionals as part of good clinical practice....
8 November 2010 - by Dr Nadeem Shaikh 
The US Department of Justice (DOJ) has weighed in on the complex issue of gene patenting against the principle that genes should be eligible for patent protection, reversing the government's position on the matter and causing consternation for many biotechnology companies. This week it issued a legal brief as a 'friend of the court' joining a lawsuit challenging the rights of companies to patent genetic technologies....
14 June 2010 - by MacKenna Roberts 
The Australian Federal Court in Sydney is considering groundbreaking legal action of whether private companies can obtain patents on human genes....
5 June 2010 - by Dr Lux Fatimathas 
Cancer patients in the UK are to be treated with drugs specific to the genetic make-up of their individual tumours. A new initiative, to be launched by the NHS this autumn, will test the tumours of up to 6000 cancer patients a year for known genetic mutations....
6 April 2010 - by Dr Vivienne Raper 
A US judge has invalidated a genetic testing company's patents on two breast cancer genes...
1 February 2010 - by MacKenna Roberts 
A landmark US lawsuit is due to begin this week in New York which will question the right of private companies to hold patents on disease-related genes and their exclusive license rights to be the sole provider of genetic tests for those diseases. Last May, lawyers from the American Civil Liberties Union (ACLU) and the Public Patent Foundation, filed a legal action that challenged seven US patents for two genes linked to hereditary breast and ovarian cancers. The action was lau...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.